BROWSE

Related Researcher

Author

Kang, Byoung Heon
Cancer Biology Lab
Research Interests
  • Mitochondrial chaperones, cancer biology, cell death, metabolism, cancer stem cells, cancer therapeutics development

ITEM VIEW & DOWNLOAD

Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer

Cited 0 times inthomson ciCited 24 times inthomson ci
Title
Preclinical Characterization of Mitochondria-Targeted Small Molecule Hsp90 Inhibitors, Gamitrinibs, in Advanced Prostate Cancer
Author
Kang, Byoung HeonSiegelin, Markus D.Plescia, JanetRaskett, Christopher M.Garlick, David S.Dohi, TakehikoLian, Jane B.Stein, Gary S.Languino, Lucia R.Altieri, Dario C.
Keywords
CELL-DEATH; BONE METASTASIS; PERMEABILITY TRANSITION; OXIDATIVE STRESS; DRUG DISCOVERY; PROTECTS CELLS; APOPTOSIS; RESISTANCE; MECHANISMS; PROMOTES
Issue Date
201010
Publisher
AMER ASSOC CANCER RESEARCH
Citation
CLINICAL CANCER RESEARCH, v.16, no.19, pp.4779 - 4788
Abstract
Purpose: This study aimed to characterize the preclinical activity of the first class of combinatorial, mitochondria-targeted, small molecule heat shock protein-90 (Hsp90) inhibitors, gamitrinibs, in models of hormone-refractory, drug-resistant, localized, and bone metastatic prostate cancer in vivo. Experimental Design: Mitochondrial permeability transition, apoptosis, and changes in metabolic activity were examined by time-lapse videomicroscopy, multiparametric flow cytometry, MTT, and analysis of isolated mitochondria. Drug-resistant prostate cancer cells were generated by chronic exposure of hormone-refractory PC3 cells to the Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG). The effect of gamitrinibs on s.c. or intratibial prostate cancer growth was studied in xenograft models. Bone metastatic tumor growth and bone parameters were quantified by micro-computed tomography imaging. Results: In the NCI 60-cell line screening, gamitrinibs were active against all tumor cell types tested, and efficiently killed metastatic, hormone-refractory, and multidrug-resistant prostate cancer cells characterized by overexpression of the ATP binding cassette transporter P-glycoprotein. Mechanistically, gamitrinibs, but not 17-AAG, induced acute mitochondrial dysfunction in prostate cancer cells with loss of organelle membrane potential, release of cytochrome c, and caspase activity, independently of proapoptotic Bcl-2 proteins Bax and Bak. Systemic administration of gamitrinibs to mice was well tolerated, and inhibited s.c. or bone metastatic prostate cancer growth in vivo. Conclusions: Gamitrinibs have preclinical activity and favorable safety in models of drug-resistant and bone metastatic prostate cancer in vivo.
URI
Go to Link
DOI
http://dx.doi.org/10.1158/1078-0432.CCR-10-1818
ISSN
1078-0432
Appears in Collections:
SLS_Journal Papers

find_unist can give you direct access to the published full text of this article. (UNISTARs only)

Show full item record

qr_code

  • mendeley

    citeulike

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

MENU